The upregulation of HDAC and CTSL enzymes in cancer has previously been exploited in a prodrug strategy whereby an ε-acetylated lysine linkage was selectively cleaved to release an active drug in a stepwise manner (Figure 9a) [47]. This evidence concerns the gene CTSL and cancer.